Underwood, M.; Urbaityte, R.; Wang, R.; Horton, J.; Oyee, J.; Wynne, B.; Fox, D.; Jones, B.; Man, C.; Sievers, J.
Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies. Viruses 2024, 16, 405.
https://doi.org/10.3390/v16030405
AMA Style
Underwood M, Urbaityte R, Wang R, Horton J, Oyee J, Wynne B, Fox D, Jones B, Man C, Sievers J.
Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies. Viruses. 2024; 16(3):405.
https://doi.org/10.3390/v16030405
Chicago/Turabian Style
Underwood, Mark, Rimgaile Urbaityte, Ruolan Wang, Joe Horton, James Oyee, Brian Wynne, Dainielle Fox, Bryn Jones, Choy Man, and Jörg Sievers.
2024. "Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies" Viruses 16, no. 3: 405.
https://doi.org/10.3390/v16030405
APA Style
Underwood, M., Urbaityte, R., Wang, R., Horton, J., Oyee, J., Wynne, B., Fox, D., Jones, B., Man, C., & Sievers, J.
(2024). Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies. Viruses, 16(3), 405.
https://doi.org/10.3390/v16030405
